Evidence map›Paper›PMID 40720755›Full record

ArticleChemMedChem2025

A Short Peptide Inhibitor of Measles Virus Fusion Protein that Exhibits Passive Membrane Permeability.

Ziwei Gao, Jiei Sasaki, Tateki Suzuki, Shinsuke Sando, Takao Hashiguchi, Jumpei Morimoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ziwei GaoDepartment of Chemistry & Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0009-0008-7233-3687
Jiei SasakiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, 606-8507, Japan.ORCID https://orcid.org/0000-0002-5129-2336
Tateki SuzukiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, 606-8507, Japan.ORCID https://orcid.org/0000-0002-6946-3850
Shinsuke SandoDepartment of Chemistry & Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0003-0275-7237
Takao HashiguchiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, 606-8507, Japan.ORCID https://orcid.org/0000-0001-7578-7571
Jumpei MorimotoDepartment of Chemistry & Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0002-8393-9616

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
AMED JP24jf0126002AMED JP24wm0325069CREST JPMJCR21N5Japan Science and Technology AgencyJSPS Core-to-Core Program JPJSCCA20240006JSPS KAKENHI JP20K20596JSPS KAKENHI JP23H02725JST PRESTO JPMJPR21AFNational Institute of Allergy and Infectious DiseasesNIGMS NIH HHS R01 GM129325NIH HHS R01-GM129325The Naito FoundationThe Uehara Memorial Foundation
6 · The paper itself

Abstract

In this study, a passively membrane-permeable short peptide inhibitor targeting the measles virus fusion protein (MeV-F) is reported. Measles virus (MeV) is highly contagious, yet no approved antiviral drugs are currently available. MeV-F plays a crucial role in viral infection, making it an attractive target for drug development. The fusion inhibitor peptide (FIP) is a well-known short peptide that binds to MeV-F and prevents its structural rearrangement. However, improving both inhibitory activity and passive membrane permeability is essential for developing orally available MeV-F inhibitors. Herein, FIP derivatives are explored through hydrogen-to-fluorine substitution and a derivative with enhanced inhibitory activity (IC

Indexed as

Antiviral AgentsMeasles virusPeptidesViral Fusion Protein InhibitorsViral Fusion ProteinsCell Membrane PermeabilityDose-Response Relationship, DrugHumansMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAntiviral AgentsPeptidesViral Fusion Protein InhibitorsViral Fusion Proteinsfluorinationfusion inhibitor peptidesmeasles virusmembrane permeability

Identifiers

PMID40720755
PMCPMC12444810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.